• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, November 16, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Bacterial Toxin Structural Mimicry Exploited to Develop Novel Cancer Immunotherapy

by
November 16, 2026
in Health
Reading Time: 6 mins read
0
Bacterial Toxin Structural Mimicry Exploited to Develop Novel Cancer Immunotherapy

Bacterial Toxin Structural Mimicry Exploited to Develop Novel Cancer Immunotherapy

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Researchers have determined the high-resolution architecture of the Escherichia coli cytotoxic necrotizing factor 1 (CNF1) toxin, revealing that the bacterial protein hijacks a host cell receptor by mimicking the structural signature of a natural human extracellular matrix ligand. The study, published in Nature Communications, elucidates how the CNF1 toxin effectively competes for binding to the Lutheran/Basal Cell Adhesion Molecule (Lu/BCAM), a receptor critical for maintaining tissue architecture. By establishing the structural basis of this molecular mimicry, the research team not only clarified a longstanding mechanism of bacterial invasion but also leveraged the toxin’s high-affinity interaction domain to engineer a novel T-cell engager (TCE) capable of directing immune cells to destroy BCAM-overexpressing tumor cells. This translational research provides a potential framework for treating malignancies such as ovarian cancer, where BCAM is frequently dysregulated and highly expressed on the cell surface.

CNF1 is a 1014-amino-acid toxin secreted by pathogenic E. coli strains associated with urinary tract infections and meningitis. Once it gains entry into a host cell, the toxin’s C-terminal catalytic domain (D5) exerts its toxicity by deamidating Glutamine 63 in RhoA or Glutamine 61 in Rac1 and Cdc42. This modification permanently locks these Rho GTPases in their active, GTP-bound state, leading to massive cytoskeletal rearrangements characterized by stress fiber formation and membrane ruffling, which facilitate bacterial uptake. The physiological function of the Lu/BCAM receptor, a single-pass transmembrane glycoprotein belonging to the immunoglobulin superfamily, is primarily linked to its interaction with laminin 511, an isoform of the basement membrane scaffold. Lu/BCAM binds to laminin 511 to mediate critical biological processes, including cell adhesion, movement, and migration. Given that Lu/BCAM serves as a portal for both bacterial infection and essential host physiology, the molecular hierarchy of these competing interactions has remained an unresolved question in microbiology.

Using cryo-electron microscopy (cryo-EM), the investigators resolved the full-length structure of CNF1 at 2.94 Å, revealing an elongated architecture where the catalytic D5 domain is positioned differently than in the homologous protein CNFY from Yersinia pseudotuberculosis. In CNF1, the D5 domain is sandwiched between the D2 and D4 domains, leaving the catalytic triad (C866/H881/V833) fully exposed to the solvent. Despite this exposure, biochemical assays revealed that full-length CNF1 exhibits weaker deamidation activity compared to the isolated D5 domain. The team concluded that the packing of the D1 through D4 domains imposes functional autoinhibition, likely limiting the conformational plasticity required for efficient engagement with Rho GTPases in the host cytosol. This structural configuration ensures that the toxin’s enzymatic potential is fully unleashed only after the protein has undergone endosomal processing and translocation into the cytoplasm, where acidic conditions trigger the release of the D5 domain.

The structural analysis of the CNF1-BCAM complex revealed that the toxin targets the V2 domain of the BCAM receptor, utilizing its D5 beta-26 region (residues 770-776) to form the interface. This interaction was compared to the structure of the physiological laminin 511E8-BCAM complex, which the researchers solved at 2.57 Å. The comparison provided definitive evidence of molecular mimicry: laminin 511 engages the same V2 domain of BCAM through a parallel beta-sheet interaction with its own LG1 domain, effectively duplicating the binding mechanism of the toxin. The pathogen has evolved a sophisticated strategy of “beta-sheet augmentation,” ensuring that the CNF1 D5 domain binds to BCAM with a dissociation constant (Kd) of approximately 3 nM, which is higher affinity than the natural laminin 511E8 ligand (Kd approximately 10 nM). This structural mimicry allows the toxin to effectively displace physiological ligands from the cell surface.

Direct competition experiments, including competitive ELISAs and cell-based binding assays, confirmed the biological consequences of this high-affinity interaction. When plates coated with BCAM were incubated with laminin 511E8 and increasing concentrations of CNF1 D5C866S, the level of bound laminin 511E8 decreased in a concentration-dependent manner, with an IC50 of approximately 12.46 nM. Similar results were observed in SKOV3 ovarian cancer cells that overexpress BCAM, where the addition of the EGFP-CNF1 D5C866S protein dose-dependently reduced cell surface laminin 511E8 binding, yielding an IC50 of approximately 103.5 nM. Furthermore, cell adhesion assays demonstrated that while laminin 511E8 normally promotes the attachment of SKOV3 cells to coverslips, the presence of CNF1 D5C866S hindered this process, indicating that the toxin’s high-affinity binding disrupts critical cell-matrix anchorage during infection.

Recognizing that BCAM is upregulated in a spectrum of malignancies—most notably in ovarian cancer—the team leveraged the high-affinity D5 domain as a tumor-targeting moiety for a T-cell engager. They constructed fusion molecules comprising an anti-CD3 scFv (derived from blinatumomab) and the CNF1 D5C866S domain. This TCE was designed to physically bridge CD3 on T cells with BCAM on tumor cells, forcibly inducing an MHC-independent immunological synapse and triggering potent, selective tumor lysis. In vitro luciferase-based cytotoxicity assays showed that the scFvCD3-D5C866S TCE induced potent tumor cell death at low picomolar concentrations. The killing was highly specific to BCAM-expressing targets; 293T cells, which have low BCAM expression, were lysed to a significantly lesser extent. Hemolysis assays of human red blood cells incubated with the TCE for 24 hours indicated minimal off-target activity, supporting the molecule’s favorable safety profile.

To assess the in vivo therapeutic efficacy of the CNF1 D5-based TCE, the researchers employed a metastatic human ovarian cancer peritoneal cell-derived xenograft (CDX) model in NCG mice. Mice were intraperitoneally inoculated with firefly luciferase-expressing OV90 ovarian cancer cells, and tumor progression was monitored longitudinally via non-invasive bioluminescence imaging. The treatment group receiving both T cells and the TCE exhibited suppressed tumor progression and significantly prolonged survival compared to control groups receiving either T-cell monotherapy or TCE alone. Importantly, the treatment did not cause significant weight loss or other gross toxicity in the mice. Confocal imaging of the contact site confirmed that the TCE successfully induced the formation of immunological synapses and the accumulation of granzyme B, the effector molecules responsible for tumor lysis.

The study further validated these findings in a syngeneic ovarian cancer model using C57-hCD3EDG transgenic mice inoculated with ID8-hBCAM-Luc cells, which express human BCAM. In this immunocompetent setting, administration of the TCE successfully suppressed tumor progression without causing apparent systemic toxicity. Ex vivo biodistribution analysis using Cy5-labeled TCE demonstrated robust and selective homing of the therapeutic molecule to the tumor, with minimal accumulation observed in major organs such as the heart, liver, spleen, lungs, and kidneys at 4 and 24 hours post-injection. This selective biodistribution is critical for reducing potential toxicity against normal tissues that might express lower levels of the BCAM receptor, and the study underscores the flexibility of the approach by demonstrating that potency can be tuned through affinity modification of the targeting moiety.

Although these results provide a compelling proof-of-concept for repurposing the “toxin-receptor” interface for precision medicine, the researchers acknowledge several limitations. While the high-affinity D5 domain is effective at targeting BCAM-expressing cells, the absolute scale of laminin displacement by CNF1 in the complex in vivo environment remains difficult to definitively establish. Furthermore, given the broad tissue distribution of the Lu/BCAM receptor, any future preclinical development of this TCE strategy must include comprehensive behavioral and physiological assessments to rule out potential neurotoxicity or motor deficits. The researchers suggested that the CNF1 D5-based blockade might also have broader clinical utility, such as preventing HIV dissemination, as BCAM has been linked to the migration of infected monocytes across endothelial barriers. The finding that CNF1 may act as a structural mimic of host proteins highlights a sophisticated evolutionary adaptation that, when carefully managed, can be harnessed to direct immune responses against tumor cells.

In conclusion, the structural determination of full-length CNF1 successfully explains how the toxin hijacks the BCAM receptor through high-affinity structural mimicry, effectively competing with physiological laminin 511. The resulting insights into the CNF1 invasion pathway not only elucidate the microbiological pathogenesis of E. coli infection but also demonstrate a clear roadmap for therapeutic development. By repurposing the toxin’s D5 domain, the study effectively redirected T cells to lyse BCAM-overexpressing ovarian tumor cells, providing a scalable strategy for targeting malignancies where this receptor is dysregulated. The research marks a significant step forward in understanding bacterial-host interfaces and offers a potent, selective framework for future immunotherapy candidates that can be tuned to maximize efficacy while maintaining a favorable safety profile across both immunodeficient and immunocompetent mouse models.

Subject of Research: Structural basis of molecular mimicry by E. coli CNF1 toxin and its application in targeted T-cell engager therapy for cancer.

Article Title: Structural basis of laminin mimicry by E. coli CNF1 and its therapeutic potential for cancer immunotherapy

Article References: Zheng, Y., Tang, Y., Wang, M., Zhang, J., Chen, J., Peng, Y., Shen, X., Zhang, S., Chen, L., Guo, Y., Sun, J., & Zhou, C. (2026). Structural basis of laminin mimicry by E. coli CNF1 and its therapeutic potential for cancer immunotherapy. Nature Communications, 17(1), Article 11017. https://doi.org/10.1038/s41467-026-77975-2

Image Credits: AI Generated

DOI: 10.1038/s41467-026-77975-2

Keywords: E. coli, CNF1 toxin, Lu/BCAM receptor, laminin 511, structural biology, cryo-electron microscopy, molecular mimicry, Rho GTPases, deamidase, T-cell engager, immunotherapy, ovarian cancer, metastasis, precision medicine, biochemical analysis, protein engineering, immunological synapse, X-ray crystallography, translational research

News Source: Nathaniel Bowman. (November 16, 2026). Bacterial Toxin Structural Mimicry Exploited to Develop Novel Cancer Immunotherapy. Scienmag.

Tags: biochemical analysisCNF1 toxincryo-electron microscopydeamidaseE. coliimmunological synapseimmunotherapylaminin 511Lu/BCAM receptorMetastasismolecular mimicryOvarian cancerPrecision MedicineProtein EngineeringRho GTPasesstructural biologyT-cell engagerTranslational ResearchX-ray crystallography
Share12Tweet7Share2ShareShareShare1

Related Posts

AI System Screens for Major Depressive Disorder Using Routine Laboratory Tests

AI System Screens for Major Depressive Disorder Using Routine Laboratory Tests

November 16, 2026
Autistic Brains Demonstrate Distinct Responsivity to Pharmacological Neurotransmitter Modulation

Autistic Brains Demonstrate Distinct Responsivity to Pharmacological Neurotransmitter Modulation

November 16, 2026

PTPN13 Gene Variant rs989902 Linked to Colorectal and Gastric Cancer Risk

November 16, 2026

Protein IGF2BP2 Controls Tumor Cell Metabolism Through Mitochondrial Transporters and Lipids

November 16, 2026

POPULAR NEWS

  • Fermented Brown Algae Postbiotic Alleviates Vascular Aging Across Multiple Animal Models

    Fermented Brown Algae Postbiotic Alleviates Vascular Aging Across Multiple Animal Models

    29 shares
    Share 12 Tweet 7
  • Myocardial Strain Imaging Detects Early Biventricular Dysfunction Across Cirrhosis Stages

    29 shares
    Share 12 Tweet 7
  • Distinct Migratory Dendritic Cells Cooperate to Prime Resident T Cells in Tumors

    29 shares
    Share 12 Tweet 7
  • Adding Ociperlimab to Tislelizumab Fails to Improve Advanced Esophageal Cancer Survival

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

AI System Screens for Major Depressive Disorder Using Routine Laboratory Tests

Autistic Brains Demonstrate Distinct Responsivity to Pharmacological Neurotransmitter Modulation

Three Ginseng Peptides Inhibit Dipeptidyl Peptidase-IV in Computational and Laboratory Tests

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.